Manufacturers: AN2 Therapeutics, Inc.
AN-15368 (also known as AN2-502998 / AN2 502998) is an orally bioavailable, boron-containing heterocyclic small molecule being developed by AN2 Therapeutics. It is a prodrug activated by parasite carboxypeptidases to yield a compound that targets the messenger RNA processing pathway, acting as a CPSF3 inhibitor. It is under development for Chagas disease (Trypanosoma cruzi infection).
AN-15368 (also known as AN2-502998 / AN2 502998) is an orally bioavailable, boron-containing heterocyclic small molecule being developed by AN2 Therapeutics. It is a prodrug activated by parasite carboxypeptidases to yield a compound that targets the messenger RNA processing pathway, acting as a CPSF3 inhibitor. It is under development for Chagas disease (Trypanosoma cruzi infection).
1 associated conditions
One entry per invention. Patent families filed in the US, EP, WO and CN offices.
No patents found under this name
Patent documents usually refer to a drug by its chemical name or development code rather than its generic name, and applications are only published about 18 months after filing — so a newer drug may not appear here yet.
